Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 2/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.60 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30673965 | 1.00 | MAP3K7 (1.00) | MAP3K7MAPK13TAB1MAPK14MAPK12 | |
| SCHEMBL5066510 | 0.88 | MAP3K7 (0.78) | MAP3K7MAPK13TAB1MAPK14MAPK12 | |
| SCHEMBL5058615 | 0.86 | MAP3K7 (0.75) | MAP3K7MAPK13TAB1MAPK14MAPK12 | |
| SCHEMBL2927745 | 0.85 | MAP3K7 (0.73) | MAP3K7TAB1RAF1DDR2AURKA | |
| SCHEMBL1410397 | 0.81 | MAPK13 (0.81) | MAP3K7MAPK13MAPK14MAPK12MAPK11 | |
| SCHEMBL2616942 | 0.81 | MAPK14 (0.75) | MAP3K7MAPK13MAPK14MAPK12MAPK11 | |
| SCHEMBL2082517 | 0.80 | MAP3K7 (0.66) | MAP3K7MAPK13TAB1MAPK14MAPK12 | |
| SCHEMBL2080408 | 0.80 | MAPK14 (0.77) | MAP3K7MAPK13MAPK14MAPK12MAPK11 | |
| SCHEMBL2082582 | 0.79 | MAPK14 (0.76) | MAP3K7MAPK13MAPK14MAPK12MAPK11 | |
| SCHEMBL2243340 | 0.79 | MAPK14 (0.75) | MAP3K7MAPK13TAB1MAPK14MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205286-A1 | Methods and Compositions for Treating Autophagy Related Disease States and Conditions Utilizing AMPK Activation | UNM RAINFOREST INNOVATIONS (US) | 2021-07-08 | — | — | US | claimed |
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-09-11 | — | — | US | disclosed |
| CN-118284420-A | Methods and compositions for treating chronic inflammatory lesions, metaplasias, dysplasias, and cancers of epithelial tissue | 休斯敦大学体系 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023239422-A2 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11819498-B2 | Methods and compositions for treating autophagy related disease states and conditions utilizing AMPK activation | UNM RAINFOREST INNOVATIONS (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-07-27 | — | — | US | disclosed |
| US-20210205286-A1 | Methods and Compositions for Treating Autophagy Related Disease States and Conditions Utilizing AMPK Activation | UNM RAINFOREST INNOVATIONS (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | MAP3K7 1978/4885MAPK13 1742/4885TAB1 1698/4885 |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | MAP3K7 1978/4885MAPK13 1742/4885TAB1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.